Financial Performance - Total revenue for Q1 2025 reached $203.5 million, a 21% increase compared to $168.5 million in Q1 2024[7, 45] - Oncology revenue grew by 20% year-over-year, reaching $150.6 million in Q1 2025 compared to $125.7 million in Q1 2024[10, 45] - Biopharma & Data revenue increased by 21% year-over-year, reaching $45.4 million in Q1 2025 compared to $37.6 million in Q1 2024[7, 27, 45] - Screening revenue for Q1 2025 was $5.7 million[7, 30, 45] - The company is raising revenue guidance for the full year 2025 to $880 million - $890 million, representing a 19%-20% year-over-year growth[52] Product and Technology Updates - Oncology volume increased by 25% year-over-year[10] - Guardant360 ASP improved to $3,000-$3,100[11] - Launched upgraded Guardant360 Tissue, a broad multiomic tissue CGP test[14, 15] - Reveal CRC & Shield are gross margin positive following significant COGS reductions[46] Screening - Shield Q1 '25 Revenue is $5.7M and Volume is 9K[30] - Shield has achieved positive gross margin ahead of schedule[36] - Improved Medicare pricing for CRC screening from $920 to $1,495, effective April 1, 2025[34]